A Phase 4 interventional study of Rebif® in Multiple Sclerosis, sponsored by EMD Serono. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-23.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.
Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 34th largest by enrollment, is one of 3 that started in 2014, is one of 15 in phase 4, and was the 31st registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 8 · Phase 4 15
First in 1999; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 85 across the 34 interventional studies. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany: none open now, 1 under way, none of them phase 3. Of 70 finished, 42 (60%) have results posted.
Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, this one is the 33rd largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2014, is one of 11 in phase 4, and was the 53rd registered.
Merck KGaA, Darmstadt, Germany’s Multiple Sclerosis studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 71 in Multiple Sclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase IV, prospective, open-label, multi-center trial to assess the treatment satisfaction in patients with relapsing forms of Multiple Sclerosis (MS) who are currently being treated with, but are considering discontinuing treatment with Tecfidera™.
Key inclusion Criteria:
Key exclusion Criteria:
Drug: Rebif®
Rebif® will be administered subcutaneously three times a week at a dose of 8.8 to 44 microgram (mcg) in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.
Also known as: interferon-beta-1a
Change From Baseline in Treatment Satisfaction Score Determined by the Global Satisfaction Sub-scale of the Treatment Satisfaction Questionnaire for Medication (TSQM [Version II]) at Week 24
The TSQM (Version II) is a validated tool that measures patient satisfaction with medical treatments using a 100-point scale. Global satisfaction sub-scale of TSQM was to be used to measure overall satisfaction with medication using a 100-point scale. Subject were to respond about their satisfaction or dissatisfaction with medication they are taking on a scale ranging from 0 to 100, where higher scores indicated greater satisfaction.
Time frame: Baseline, Week 24
Change From Baseline in Patient-Determined Disease Steps Questionnaire (PDDS) Score at Week 24
PDDS questionnaire was to be used to assess the walking ability of subjects. Subjects were to describe their walking ability on scale ranging from 0 to 8, where 0 indicated normal walking and 8 indicated subject's condition as bedridden. Lesser score indicated better walking ability.
Time frame: Baseline, Week 24
Change From Baseline in Multiple Sclerosis Quality of Life-54 (MSQoL-54) Score at Week 24
The MSQOL-54 is a multidimensional health-related quality of life measure that combines both generic and MS-specific items into a single instrument. MSQoL-54 is a 54 item questionnaire which covers 12 sub-scales along with two summary scores, and two additional single-item measures. The 12 sub-scales are: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. The 2 summary scores are the physical health composite summary and the mental health composite summary. The 2 additional single item measures are satisfaction with sexual function and change in health. Each of the 12 sub-scale scores, the 2 summary scores and 2 single item measures were to be converted into an overall Total Score ranging from 0-100, where higher scores indicated better health status.
Time frame: Baseline, Week 24
Change From Baseline in TSQM (Version II) - Total Score at Week 12 and Week 24
The TSQM (Version II) is an 11-item validated tool that measures patient satisfaction with medical treatments using a 100-point scale. Total TSQM score was the average of individual sub-scale scores (effectiveness, side effects, convenience and global satisfaction) and ranged from 0 to 100, where higher scores indicated greater satisfaction.
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in TSQM (Version II) - Medication Effectiveness, Side Effects, and Convenience Subscale Scores at Week 24
The TSQM (Version II) is a validated tool that measures patient satisfaction with medical treatments using a 100-point scale. Effectiveness, side effects and convenience sub-scales of TSQM were to be used to measure overall satisfaction with medication. Subject were to respond about their satisfaction or dissatisfaction with medication they are taking in terms of effectiveness, side effects and convenience, each sub-scale ranging on a scale of 0 to 100, where higher scores indicated greater satisfaction.
Time frame: Baseline, Week 24
Change From Baseline in TSQM (Version II) - Global Satisfaction, Medication Effectiveness, Side Effects, and Convenience Subscale Scores at Week 12
The TSQM (Version II) is a validated tool that measures patient satisfaction with medical treatments using a 100-point scale. Effectiveness, side effects, convenience and global satisfaction sub-scales of TSQM were to be used to measure overall satisfaction with medication. Subject were to respond about their satisfaction or dissatisfaction with medication they are taking in terms of effectiveness, side effects, convenience and global satisfaction, each sub-scale ranging on a scale of 0 to 100, where higher scores indicated greater satisfaction.
Time frame: Baseline, Week 12
Change From Baseline in Work Productivity and Activity Impairment- General Health (WPAI-GH) Questionnaire Score at Week 24
WPAI-GH questionnaire is a subject reported quantitative assessment of general health conditions on productivity. The Total WPAI-GH score assessment was to be done on an 11-point scale ranging 0 to 10, with 0 indicating that health problems had no effect on work and 10 indicating that health problems completely prevented from working.
Time frame: Baseline, Week 24
Change From Baseline in Number of Combined Unique Active (CUA) Lesions, New Time or Enlarging Constant 2 (T2) Lesions, and New Gadolinium Enhanced (Gd+) Time Constant 1 (T1) Lesions at Week 24
Time frame: Baseline, Week 24
Annualized Relapse Rate (ARR)
A relapse is defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting for at least 24 hours, and accompanied by new objective neurologic findings. Episodes indicated by neurologist as "relapse" in the subjects chart were to be recorded.
Time frame: Week 24
| Milestone | Rebif® Via Rebidose® Auto-injector |
|---|---|
| Started | 1 |
| Completed | 0 |
| Not completed | 1 |
| Withdrew: Subject enrolled but not dosed | 1 |
The TSQM (Version II) is a validated tool that measures patient satisfaction with medical treatments using a 100-point scale. Global satisfaction sub-scale of TSQM was to be used to measure overall satisfaction with medication using a 100-point scale. Subject were to respond about their satisfaction or dissatisfaction with medication they are taking on a scale ranging from 0 to 100, where higher scores indicated greater satisfaction.
No measurements were reported for this outcome.
PDDS questionnaire was to be used to assess the walking ability of subjects. Subjects were to describe their walking ability on scale ranging from 0 to 8, where 0 indicated normal walking and 8 indicated subject's condition as bedridden. Lesser score indicated better walking ability.
No measurements were reported for this outcome.
The MSQOL-54 is a multidimensional health-related quality of life measure that combines both generic and MS-specific items into a single instrument. MSQoL-54 is a 54 item questionnaire which covers 12 sub-scales along with two summary scores, and two additional single-item measures. The 12 sub-scales are: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. The 2 summary scores are the physical health composite summary and the mental health composite summary. The 2 additional single item measures are satisfaction with sexual function and change in health. Each of the 12 sub-scale scores, the 2 summary scores and 2 single item measures were to be converted into an overall Total Score ranging from 0-100, where higher scores indicated better health status.
No measurements were reported for this outcome.
The TSQM (Version II) is an 11-item validated tool that measures patient satisfaction with medical treatments using a 100-point scale. Total TSQM score was the average of individual sub-scale scores (effectiveness, side effects, convenience and global satisfaction) and ranged from 0 to 100, where higher scores indicated greater satisfaction.
No measurements were reported for this outcome.
The TSQM (Version II) is a validated tool that measures patient satisfaction with medical treatments using a 100-point scale. Effectiveness, side effects and convenience sub-scales of TSQM were to be used to measure overall satisfaction with medication. Subject were to respond about their satisfaction or dissatisfaction with medication they are taking in terms of effectiveness, side effects and convenience, each sub-scale ranging on a scale of 0 to 100, where higher scores indicated greater satisfaction.
No measurements were reported for this outcome.
The TSQM (Version II) is a validated tool that measures patient satisfaction with medical treatments using a 100-point scale. Effectiveness, side effects, convenience and global satisfaction sub-scales of TSQM were to be used to measure overall satisfaction with medication. Subject were to respond about their satisfaction or dissatisfaction with medication they are taking in terms of effectiveness, side effects, convenience and global satisfaction, each sub-scale ranging on a scale of 0 to 100, where higher scores indicated greater satisfaction.
No measurements were reported for this outcome.
WPAI-GH questionnaire is a subject reported quantitative assessment of general health conditions on productivity. The Total WPAI-GH score assessment was to be done on an 11-point scale ranging 0 to 10, with 0 indicating that health problems had no effect on work and 10 indicating that health problems completely prevented from working.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
A relapse is defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting for at least 24 hours, and accompanied by new objective neurologic findings. Episodes indicated by neurologist as "relapse" in the subjects chart were to be recorded.
No measurements were reported for this outcome.
Collected over The study was prematurely terminated due to one subject enrolled but not dosed. Thus, data for adverse events was not collected.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rebif® Via Rebidose® Auto-injector | — | — | — |
| Age, Categorical(Participants) | Rebif® Via Rebidose® Auto-injector |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 1 |
| >=65 years | 0 |
| Sex/Gender, Customized(subject) | Rebif® Via Rebidose® Auto-injector |
|---|---|
| Prefers not to identify | 1 |
The record gives a start of Jun 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a